Daratumumab Emerging Drug Insight

“Daratumumab Market Size, Forecast, and Emerging Insight – 2032” report provides comprehensive insights about Daratumumab for AL Amyloidosis in the 7MM. A detailed picture of the Daratumumab for AL Amyloidosis in the 7MM, i.e., United States, EU4 (Germany, France, Italy, Spain), and the United Kingdom, and Japan, for the study period 2019–2032 is provided in this report along with a detailed description of the Daratumumab for AL Amyloidosis. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the Daratumumab market forecast, analysis for AL Amyloidosis in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about emerging therapies in AL Amyloidosis.

Drug Summary

Daratumumab (DARZALEX) is an IgG1k monoclonal antibody and CD38 directed targeted therapy that binds to CD38. Daratumumab binds to a different CD38 epitope amino-acid sequence than those that cause cell apoptosis via antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, or antibody-dependent cellular phagocytosis. These effects are dependent upon fragment crystallizable region immune effector mechanisms. Antibody-dependent cellular cytotoxicity utilises natural killer cells. DARZALEX FASPRO is a subcutaneous formulation of daratumumab co-formulated with recombinant human hyaluronidase PH20 (rHuPH20), developed using ENHANZE drug delivery technology to enhance penetration through the skin.

Genmab originally developed Daratumumab, but Genmab is jointly developing it along with the Johnson & Johnson subsidiary Janssen Biotech, which acquired worldwide commercialization rights to the drug from Genmab. Daratumumab was awarded orphan drug status for multiple myeloma, AL amyloidosis, diffuse large B cell lymphoma, follicular lymphoma, and mantle cell lymphoma. The US FDA granted accelerated approval for Daratumumab, based on the results and response of the Phase III ANDROMEDA trial, as the first line for the treatment of AL amyloidosis in combination with bortezomib, cyclophosphamide, and dexamethasone (CyBorD) (Janssen Biotech, 2021b). Continued approval for this indication may be subject to chance upon verification and description of clinical benefit in a confirmatory trial.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the Daratumumab description, mechanism of action, dosage and administration, research and development activities in AL Amyloidosis.
• Elaborated details on Daratumumab regulatory milestones and other development activities have been provided in this report.
• The report also highlights the Daratumumab research and development activity in AL Amyloidosis details across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around Daratumumab.
• The report contains forecasted sales of Daratumumab for AL Amyloidosis till 2032.
• Comprehensive coverage of the late-stage emerging therapies for AL Amyloidosis.
• The report also features the SWOT analysis with analyst views for Daratumumab in AL Amyloidosis.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Daratumumab Analytical Perspective by DelveInsight

• In-depth Daratumumab Market Assessment

This report provides a detailed market assessment of Daratumumab in AL Amyloidosis in the 7MM, i.e., United States, EU4 (Germany, France, Italy, Spain), and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

• Daratumumab Clinical Assessment

The report provides the clinical trials information of Daratumumab for AL Amyloidosis covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for AL Amyloidosis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market. 
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Daratumumab dominance.
• Other emerging products for AL Amyloidosis are expected to give tough market competition to Daratumumab and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Daratumumab in AL Amyloidosis.
• Our in-depth analysis of the forecasted sales data of Daratumumab from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Daratumumab in AL Amyloidosis.

Key Questions

• What is the product type, route of administration and mechanism of action of Daratumumab?
• What is the clinical trial status of the study related to Daratumumab in AL Amyloidosis and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Daratumumab development?
• What are the key designations that have been granted to Daratumumab for AL Amyloidosis?
• What is the forecasted market scenario of Daratumumab for AL Amyloidosis?
• What are the forecasted sales of Daratumumab in the 7MM, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available in AL Amyloidosis and how are they giving competition to Daratumumab for AL Amyloidosis?
• Which are the late-stage emerging therapies under development for the treatment of AL Amyloidosis?